Skip to content
thestock.space

Entero Healthcare Solutions (ENTERO) had a P/E of 66.0× on 6 Nov 2026, above the industry P/E of 36.7×. Sales grew 26% a year over 3 years, with ROCE of 11% and ROE of 6.7%. Debt is 0.39× equity. It is a small-cap company with a market cap of ₹8,279 Cr, the largest of 11 Medical Distribution companies by market cap; the shares rose 62% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹1,768.80
Day high
₹1,936.60
Day low
₹1,761.30
Prev. close
₹1,754.10
Volume
12.1 L

Health check

1 good · 3 fair · 2 to check
  • ReturnsAhead

    +62.4% over a year, better than 5 of 7 peers.

  • Price tagPricier

    P/E 66.0 vs industry 36.7.

  • GrowthSteady

    Sales +25.7% a year over 3 years.

  • ProfitabilityAverage

    ROCE 11.3% vs peer median 4.4%.

  • Balance sheetFair

    Debt 0.39× equity, interest covered 4.7×, Piotroski 5 of 9.

  • Red flags2 to check

    Return on equity is low at 6.7%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Medical Distribution

10 listed peers. Screen the industry

Small cap

₹8,279 Cr, the largest of 11 in its industry.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹7,128 Cr · profit ₹125 Cr
Market cap
₹8,279 Cr
Small cap
P/E
66.0
Industry 36.7
Price to book
4.90
Peers 1.16
Dividend yield
0.00%
ROE
6.7%
Peers 8.0%
ROCE
11.3%
Peers 4.4%
Debt to equity
0.39
Debt ₹677 Cr
EPS (TTM)
₹28.78
Face value ₹10
OPM (TTM)
4.4%
Net margin 1.8%
Sales growth
+38.2%
Latest quarter vs a year ago
Profit growth
+37.3%
Latest quarter vs a year ago
Price to sales
1.16
EV/EBITDA 27.4

Strengths and risks

Strengths

  • Quarterly profit up 37.3% on a year ago.
  • Quarterly sales up 38.2% on a year ago.

Risks to check

  • Return on equity is low at 6.7%.
  • P/E of 66.0 against an industry P/E of 36.7.

Derived automatically from reported figures. Not a recommendation.

About Entero Healthcare Solutions

Entero Healthcare Solutions Limited engages in the trading of pharmaceutical and surgical products in India. The company offers a range of pharmaceuticals and other healthcare products to retail pharmacies and healthcare practitioners; and healthcare products, including pharmaceutical and nutraceutical products and vaccines; medical devices, such as orthopaedic implants and coronary stents; and hospital consumables comprising examination and surgical…

Headquarters
Mumbai
Employees
4,671
Sector
Healthcare
ISIN
INE010601016
Website
enterohealthcare.com

Price range

52 weeks

₹944.00₹1,936.60

Today

₹1,761.30₹1,936.60
Avg volume (3M)
3.1 L
1-year return
plus 62.4%
From 52-week high
minus 1.9%

Analyst consensus

5 analysts
No consensusMean target ₹1,844.40 minus 2.9%

The mean target is below today’s price.

Target range, with today’s price

Low ₹1,590.00High ₹2,132.00

Consensus from Yahoo Finance. Not a recommendation.

Peers · Medical Distribution

Compare with peersScreen the whole industry
Company
ENTEROEntero Healthcare Solutions1,900.40plus 8.34%8,27966.04.9011.3%6.7%4.4%25.7%–0.00%plus 62.4%
APPLAptus Pharma465.00plus 0.92%797100.228.0629.3%31.7%15.4%49.6%187.5%0.00%plus 772.6%
ARVAYAArvaya Healthcare111.00minus 4.31%576––1.4%2.2%0.0%193.6%–0.00%plus 143.1%
EVEXIAEvexia Lifecare1.46minus 3.31%274146.00.670.3%0.3%1.6%16.6%34.5%0.00%minus 15.2%
NOVELIXNovelix Pharmaceuticals64.66minus 4.91%18436.72.937.4%8.0%3.1%354.8%–0.00%plus 29.5%
AMWILLAmwill Health Care44.00plus 5.67%887.81.0615.5%14.4%14.1%14.7%54.2%2.27%minus 25.4%
CBPLChandra Bhagat Pharma55.50minus 4.31%4213.71.26–9.7%2.5%––0.00%plus 45.0%
WELCUREWelcure Drugs and Pharmaceuticals0.18minus 5.26%22–0.23−5.7%−5.5%−1.5%––0.00%minus 62.7%
Median of 7 peers–−4.31%18436.71.164.4%8.0%2.5%49.6%54.2%0.00%29.5%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
1,4041,5711,7071,9101,940
1,3541,5091,6391,8241,844
50.162.167.88697
3.6%4.0%4.0%4.5%5.0%
5.84.84.643
10.712.41417.320.6
8.99.89.814.812.3
––−8.2––
36.444.640.457.967.1
16.9%18.0%16.1%22.1%22.5%
27.831.627.62838.2
6.387.256.346.438.76

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+25.7%
ROE
6.7%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
3,2933,8885,0656,540
–+18.1%+30.3%+29.1%
3,2293,7764,8936,274
64112173266
1.9%2.9%3.4%4.1%
0.99.233.99.1
44.460.537.549
24.22530.743.3
–00.2−3.9
−3.735.6139179
−201.1%−11.9%22.6%18.7%
−11.639.194.8115
––+142.5%+21.3%
-2.6610.8121.7626.40

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
4.143.543.543.5
5911,5951,6811,645
438338385677
2763695931,235
1,3092,3452,7033,600
96.993.1132201
–––1.1
1.415.726.24.9
107788373296
1,1041,4482,1713,097
1,3092,3452,7033,600

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
−45.3−36.6−76.996.2
−48.6−705220−303
72.8863−73.7124
−21.112169.3−83.2
−5.5−5.4−11.3−67.5
−50.8−42−88.228.7

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 24.4% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you